JP7748386B2 - がんの治療で使用するためのミルダメチニブ及びリフィラフェニブの同時投与 - Google Patents

がんの治療で使用するためのミルダメチニブ及びリフィラフェニブの同時投与

Info

Publication number
JP7748386B2
JP7748386B2 JP2022560245A JP2022560245A JP7748386B2 JP 7748386 B2 JP7748386 B2 JP 7748386B2 JP 2022560245 A JP2022560245 A JP 2022560245A JP 2022560245 A JP2022560245 A JP 2022560245A JP 7748386 B2 JP7748386 B2 JP 7748386B2
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
per day
salt form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022560245A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023521036A (ja
JP2023521036A5 (enExample
Inventor
ルソン ルオ，
ジユ タン，
バドレディン エドゥリス，
トッド ウェブスター シアラー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SpringWorks Therapeutics Inc
Original Assignee
SpringWorks Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SpringWorks Therapeutics Inc filed Critical SpringWorks Therapeutics Inc
Publication of JP2023521036A publication Critical patent/JP2023521036A/ja
Publication of JP2023521036A5 publication Critical patent/JP2023521036A5/ja
Priority to JP2025102055A priority Critical patent/JP2025120501A/ja
Application granted granted Critical
Publication of JP7748386B2 publication Critical patent/JP7748386B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022560245A 2020-04-03 2021-04-02 がんの治療で使用するためのミルダメチニブ及びリフィラフェニブの同時投与 Active JP7748386B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025102055A JP2025120501A (ja) 2020-04-03 2025-06-18 がんの治療で使用するためのミルダメチニブ及びリフィラフェニブの同時投与

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063005153P 2020-04-03 2020-04-03
US63/005,153 2020-04-03
PCT/US2021/025551 WO2021202981A1 (en) 2020-04-03 2021-04-02 Co-administration of mirdametinib and lifirafenib for use in treating cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025102055A Division JP2025120501A (ja) 2020-04-03 2025-06-18 がんの治療で使用するためのミルダメチニブ及びリフィラフェニブの同時投与

Publications (3)

Publication Number Publication Date
JP2023521036A JP2023521036A (ja) 2023-05-23
JP2023521036A5 JP2023521036A5 (enExample) 2024-04-11
JP7748386B2 true JP7748386B2 (ja) 2025-10-02

Family

ID=75674969

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022560245A Active JP7748386B2 (ja) 2020-04-03 2021-04-02 がんの治療で使用するためのミルダメチニブ及びリフィラフェニブの同時投与
JP2025102055A Pending JP2025120501A (ja) 2020-04-03 2025-06-18 がんの治療で使用するためのミルダメチニブ及びリフィラフェニブの同時投与

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025102055A Pending JP2025120501A (ja) 2020-04-03 2025-06-18 がんの治療で使用するためのミルダメチニブ及びリフィラフェニブの同時投与

Country Status (21)

Country Link
US (1) US12667560B2 (enExample)
EP (1) EP4125842B1 (enExample)
JP (2) JP7748386B2 (enExample)
KR (1) KR20230048476A (enExample)
CN (1) CN116194095B (enExample)
AU (1) AU2021246141A1 (enExample)
BR (1) BR112022019914A2 (enExample)
CA (1) CA3174223A1 (enExample)
CL (1) CL2022002682A1 (enExample)
CO (1) CO2022015891A2 (enExample)
DK (1) DK4125842T3 (enExample)
ES (1) ES2985012T3 (enExample)
FI (1) FI4125842T3 (enExample)
HU (1) HUE067894T2 (enExample)
IL (1) IL296878A (enExample)
MX (1) MX2022012351A (enExample)
PE (1) PE20231211A1 (enExample)
PL (1) PL4125842T3 (enExample)
PT (1) PT4125842T (enExample)
TW (1) TWI893097B (enExample)
WO (1) WO2021202981A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL4125842T3 (pl) 2020-04-03 2024-10-14 Beigene, Ltd. Równoczesne podawanie mirdametynibu i lifirafenibu do stosowania w leczeniu nowotworów
US20230293464A1 (en) * 2022-03-17 2023-09-21 SpringWorks Therapeutics Inc. Treatment of pancreatic ductal adenocarcinoma with mirdametinib
MX2024011403A (es) * 2022-03-17 2024-09-23 Springworks Therapeutics Inc Tratamiento con mirdametinib.
WO2023209611A1 (en) * 2022-04-26 2023-11-02 Beigene Switzerland Gmbh Methods of treating cancer with a b-raf inhibitor, in particular lifirafenib
EP4601631A4 (en) * 2022-10-14 2026-04-08 Springworks Therapeutics Inc COMBINATION INTENDED FOR USE IN CANCER TREATMENT

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018511634A (ja) 2015-04-15 2018-04-26 ベイジーン リミテッド Ｂ−ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004501190A (ja) 2000-06-23 2004-01-15 テバ　ファーマシューティカル　インダストリーズ　リミティド 治療薬の胃部保留および制御された放出のための急速膨張する組成物とその組成物を含む剤形
AU7349801A (en) 2000-07-19 2002-01-30 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
EP1562601A1 (en) 2002-11-15 2005-08-17 Warner-Lambert Company LLC Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer
KR101013932B1 (ko) 2003-10-21 2011-02-14 워너-램버트 캄파니 엘엘씨 Ｎ-[(ｒ)-2,3-디히드록시-프로폭시]-3,4-디플루오로-2-(2-플루오로-4-요오도페닐아미노)-벤자미드 다형체 형태
WO2006061712A2 (en) 2004-12-10 2006-06-15 Pfizer Inc. Use of mek inhibitors in treating abnormal cell growth
WO2006134469A1 (en) 2005-06-14 2006-12-21 Warner-Lambert Company Llc Methods of preparing mek inhibitor
WO2007042885A2 (en) 2005-10-07 2007-04-19 Pfizer Products Inc. Therapeutic combination comprising methotrexate and a specified inhibitor of mek1 and mek2
TR201815685T4 (tr) 2011-04-01 2018-11-21 Genentech Inc Kanser tedavisi için akt ve mek inhibe edici bileşiklerin kombinasyonları.
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
KR102811888B1 (ko) 2017-09-08 2025-05-27 에프. 호프만-라 로슈 아게 암의 진단 및 치료 방법
WO2019113345A1 (en) 2017-12-06 2019-06-13 Spyro Mousses Combination of cancer therapeutics for treatment of cancer and hyperproliferative diseases
EP3560516A1 (en) 2018-04-27 2019-10-30 Bergen Teknologioverforing AS Combination therapy including beta-sitosterol in combination with at least one of a braf inhibitor, a mek inhibitor or an erk inhibitor and methods and use thereof
US12208099B2 (en) 2018-09-10 2025-01-28 Mirati Therapeutics, Inc. Combination therapies
PL4125842T3 (pl) 2020-04-03 2024-10-14 Beigene, Ltd. Równoczesne podawanie mirdametynibu i lifirafenibu do stosowania w leczeniu nowotworów
US11066358B1 (en) 2021-02-17 2021-07-20 Warner-Lambert Company Llc Compositions of essentially pure form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
US11571402B2 (en) 2021-02-17 2023-02-07 Springworks Therapeutics, Inc. Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
US11084780B1 (en) 2021-02-17 2021-08-10 Springworks Therapeutics, Inc. Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
MX2024011403A (es) 2022-03-17 2024-09-23 Springworks Therapeutics Inc Tratamiento con mirdametinib.
PE20242177A1 (es) 2022-03-17 2024-11-07 St Jude Childrens Res Hospital Inc Tratamiento del glioma de bajo grado con mirdametinib

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018511634A (ja) 2015-04-15 2018-04-26 ベイジーン リミテッド Ｂ−ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SpringWorks Therapeutics Announces Initiation ofPhase 1b Clinical Trial of MEK Inhibitor PD-0325901in Combination with BeiGene’s RAF Dimer InhibitorLifirafenib in Advanced or Refractory Solid Tumors[online]，2019年，<URL:https://ir.springworkstx.com/news-releases/news-release-details/springworks-therapeutics-announces-initiation-phase-1b-clinical/>検索日２０２５年３月２１日
Study of the Safety and Pharmacokinetics of BGB-283(Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors[online]，2019年，<URL:https://clinicaltrials.gov/study/NCT03905148>検索日２０２５年３月２１日

Also Published As

Publication number Publication date
US20230128315A1 (en) 2023-04-27
IL296878A (en) 2022-12-01
HUE067894T2 (hu) 2024-11-28
ES2985012T3 (es) 2024-11-04
CN116194095A (zh) 2023-05-30
PL4125842T3 (pl) 2024-10-14
EP4125842A1 (en) 2023-02-08
CO2022015891A2 (es) 2023-05-08
JP2023521036A (ja) 2023-05-23
EP4125842B1 (en) 2024-06-05
TWI893097B (zh) 2025-08-11
PT4125842T (pt) 2024-08-06
US12667560B2 (en) 2026-06-30
PE20231211A1 (es) 2023-08-17
MX2022012351A (es) 2023-03-13
DK4125842T3 (da) 2024-07-22
FI4125842T3 (fi) 2024-08-06
JP2025120501A (ja) 2025-08-15
CA3174223A1 (en) 2021-10-07
CL2022002682A1 (es) 2023-06-16
KR20230048476A (ko) 2023-04-11
CN116194095B (zh) 2024-09-13
AU2021246141A1 (en) 2022-12-01
TW202207910A (zh) 2022-03-01
BR112022019914A2 (pt) 2022-12-13
WO2021202981A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
TWI893097B (zh) 用於治療癌症之米達替尼與利非芬尼之共同投藥
RS60152B1 (sr) Tapentadol za sprečavanje i lečenje depresije i anksioznosti
TW200836738A (en) Improvements in or relating to medicinal compositions
MXPA04012070A (es) Agente terapeutico para vejiga hiperactiva.
JP2022519721A (ja) 睡眠時無呼吸を治療するための方法および組成物
JP7232932B2 (ja) Ｗｓ－６３５及び医学におけるその使用
Mantz Alpha2-adrenoceptor agonists: analgesia, sedation, anxiolysis, haemodynamics, respiratory function and weaning
WO2004054586A1 (en) Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450, such as protease inhibitors
KR20250108755A (ko) 시누클레인병변을 치료하기 위한 조성물 및 방법
Moyao-García et al. A pilot study of nalbuphine versus tramadol administered through continuous intravenous infusion for postoperative pain control in children
EP3982970A1 (en) New treatment of sma
CN101754760A (zh) 用以改善伴随着前列腺肥大的下尿路症状的药物组合物
WO2018200387A1 (en) Compositions and method for treating depression
CN100418526C (zh) 依贝沙坦在制备用来预防或治疗肺动脉高压的药物中的应用
EP4117638B1 (en) Controlled release formulations comprising drotaverine or salt thereof
US8101580B2 (en) Therapeutic agent for irritable bowel syndrome
JP2022520276A (ja) ベンズイミダゾール誘導体化合物を含む医薬組成物
CN110267657B (zh) 氨基甲酸酯化合物用于预防、缓解或治疗震颤或震颤综合征的用途
CN114466683A (zh) 治疗方法及其用途
AU2020235442A1 (en) Capsid assembly modulator solid formulation
US12303503B1 (en) Use of dextromethorphan in combination with CYP2D6 and CYP3A4 enzyme inhibitors for the treatment of pain
JP6042886B2 (ja) 早漏症治療用の薬学組成物
Podolsky et al. Randomized clinical trial of the safety and efficacy of oxymorphone extended release for degenerative disc disease in opioid-naive patients
Rauck et al. Conversion and titration from oxycodone to oxymorphone extended release in patients with chronic low back pain
JPH10287568A (ja) アルコール依存症治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240401

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240401

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250321

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250618

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250822

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250919

R150 Certificate of patent or registration of utility model

Ref document number: 7748386

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150